Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
The effect of inhaled corticosteroids on airway hyperresponsiveness to mannitol in patients with Type 2 low asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Bronchial hyperresponsiveness to methacholine/AMP and the bronchodilator response in asthmatic children Source: Eur Respir J 2011; 37: 800-805 Year: 2011
Efficiency of extrafine beclometasone dipropionat/formoterol fumarate in asthma patients with cold and/or osmotic airway hyperresponsiveness (AHR) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017
Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 262s Year: 2004
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Source: Eur Respir J 2008; 32: 970-978 Year: 2008
Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Source: Eur Respir J 2002; 20: 853-858 Year: 2002
Effect of formoterol with or without budesonide in repeated low-dose allergen challenge Source: Eur Respir J 2009; 33: 747-753 Year: 2009
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
Correlation between score of Asthma Control Test (ACT) and airway hyperresponsiveness (AHR) in young adults with bronchial asthma (BA) Source: Annual Congress 2006 - New developments in the treatment and management of asthma Year: 2006
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002
Assessment of bronchial hyperreactivity, maximal airway response and response to inhaled corticosteriod treatment in patients with bronchiectasis Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison Source: Eur Respir J 2007; 30: 653-661 Year: 2007
Relationships of mannitol challenge to methacholine challenge and inflammatory markers in asthmatics receiving inhaled corticosteroids Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012
Airway inflammation and inhaled corticosteroids in COPD Source: Eur Respir J, 49 (6) 1700289; 10.1183/13993003.00289-2017 Year: 2017